🌍·4d agoIndustry
ASCO 2026 Poster Presentation: The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
Publisher
B
Bicara Therapeutics
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on bicara.com
Leave the platform to read the original full article on the publisher site.
Source: Bicara Therapeutics
Scope: Industry
Related coverage
More related coverage
Ipsen·9h ago
Choosing the hardest problems: why Ipsen focuses where unmet need is greatest
Ipsen RSS·9h ago
Choosing the hardest problems: why Ipsen focuses where unmet need is greatest
Hyman, Phelps & McNamara (FDA Law)·16h ago
FDA Issues Final Guidance for Content of Human Factors Information in Medical Device Submissions
Natco Pharma·17h ago